Pregnancy Drugs Linked to Autism Risk

New research indicates a potential link between specific medications used during pregnancy and an increased likelihood of a child developing autism spectrum disorder (ASD). The study, which analyzed approximately one-third of US births between 2014 and 2023, focused on sterol biosynthesis-inhibiting medications (SBIMs).

These medications, often prescribed for conditions like high cholesterol, were associated with a higher risk of ASD. The study found that mothers who took at least one SBIM during pregnancy had a 1.47-fold higher risk. This risk further amplified with additional SBIMs, reaching up to a 2.3-fold increase for those taking four or more.

Researchers theorize that SBIMs, which interfere with the body's cholesterol synthesis pathway, might disrupt crucial signaling molecules and cell membrane development in the fetal brain. While the exact mechanism is still under investigation, this biochemical disruption could potentially increase vulnerability to neurodevelopmental issues. Experts emphasize that pregnancy is a sensitive period and advise pregnant women to discuss all medications with their doctors.

While the study adds to the complex understanding of autism's multifactorial causes, it does not establish a sole causal link. Pregnant individuals are urged not to discontinue necessary medications without consulting healthcare professionals. Doctors are encouraged to carefully consider the benefits and risks of SBIMs for expectant mothers.